標(biāo)題: Titlebook: HIV Vaccines and Cure; The Path Towards Fin Linqi Zhang,Sharon R. Lewin Book 2018 Springer Nature Singapore Pte Ltd. 2018 HIV.Cure.Latency. [打印本頁(yè)] 作者: 矜持 時(shí)間: 2025-3-21 17:28
書(shū)目名稱(chēng)HIV Vaccines and Cure影響因子(影響力)
書(shū)目名稱(chēng)HIV Vaccines and Cure影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)HIV Vaccines and Cure網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)HIV Vaccines and Cure網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)HIV Vaccines and Cure被引頻次
書(shū)目名稱(chēng)HIV Vaccines and Cure被引頻次學(xué)科排名
書(shū)目名稱(chēng)HIV Vaccines and Cure年度引用
書(shū)目名稱(chēng)HIV Vaccines and Cure年度引用學(xué)科排名
書(shū)目名稱(chēng)HIV Vaccines and Cure讀者反饋
書(shū)目名稱(chēng)HIV Vaccines and Cure讀者反饋學(xué)科排名
作者: 吹牛者 時(shí)間: 2025-3-21 23:17
Book 2018 design of clinical trials for testing the safety and efficacy of these innovative approaches. This book will provide a systematic overview and also discuss controversial issues for researchers in virology and immunology, as well as practicing physicians, and scientists in the pharmaceutical industry..作者: foodstuff 時(shí)間: 2025-3-22 03:06
her vaccine strategies. Trials in Thailand and South Africa have built upon the RV144 framework to provide additional immunologic insights which enable current and future efficacy testing of related vaccine candidates.作者: 重畫(huà)只能放棄 時(shí)間: 2025-3-22 04:57 作者: 談判 時(shí)間: 2025-3-22 10:58
https://doi.org/10.1007/978-1-349-20768-8ter, therefore, we summarize major scientific evidence generated in these models since the beginning of the AIDS pandemic. Hopefully, the accumulated knowledge and lessons contributed by thousands of scientists will be useful in promoting the search of an ultimate solution to end HIV/AIDS.作者: 平項(xiàng)山 時(shí)間: 2025-3-22 16:12
HIV Vaccine Efficacy Trials: RV144 and Beyondher vaccine strategies. Trials in Thailand and South Africa have built upon the RV144 framework to provide additional immunologic insights which enable current and future efficacy testing of related vaccine candidates.作者: JOG 時(shí)間: 2025-3-22 20:13
HIV Broadly Neutralizing Antibodies: VRC01 and Beyond-depth understanding of the sites of vulnerability on the HIV-1 Env and the complexity of human B cell immunology to generate such responses, thus presenting both guidance and challenges to move the Env immunogen design effort forward.作者: Generic-Drug 時(shí)間: 2025-3-22 22:04 作者: 構(gòu)成 時(shí)間: 2025-3-23 05:06
0065-2598 ssing the challenges related to development of HIV vaccine a.This book provides a comprehensive review of the major barriers to HIV cure and vaccine. It covers the fundamental virology and immunology leading to HIV transmission, protection from infection and long term HIV persistence on antiretrovir作者: TEN 時(shí)間: 2025-3-23 06:11 作者: 永久 時(shí)間: 2025-3-23 10:09
https://doi.org/10.1007/978-94-6209-725-4 research in serodiscordant couples, the implications for management of couples, subsequent research on treatment as prevention in other key populations, and challenges in community implementation of these strategies.作者: Cougar 時(shí)間: 2025-3-23 17:46 作者: 的是兄弟 時(shí)間: 2025-3-23 20:41 作者: ingrate 時(shí)間: 2025-3-23 22:22 作者: 單色 時(shí)間: 2025-3-24 05:38 作者: ARCH 時(shí)間: 2025-3-24 07:30
The Molecular Biology of HIV Latencyiated, and the gaps in knowledge prevent development of adequate small-molecule compounds that can effectively perturb this reservoir. In this review, we will examine the role of epigenetic silencing of HIV transcription, posttranscriptional regulation, and mRNA processing in promoting HIV-1 latency.作者: 殺菌劑 時(shí)間: 2025-3-24 11:24
Cellular Determinants of HIV Persistence on Antiretroviral Therapynover potential are central components that allow persistence of different lymphoid and myeloid cell subsets that were recently identified as key players in harboring latent and actively replicating virus. The relative contribution of these subsets to persistence of viral reservoir is described, and the open questions are highlighted.作者: 致敬 時(shí)間: 2025-3-24 17:58
Linqi Zhang,Sharon R. LewinProviding a comprehensive review of the major barriers to HIV cure and vaccine.Covering the fundamental virology and immunology of HIV.Discussing the challenges related to development of HIV vaccine a作者: cortisol 時(shí)間: 2025-3-24 21:13
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/h/image/420205.jpg作者: 高度 時(shí)間: 2025-3-25 03:14
978-981-13-4428-2Springer Nature Singapore Pte Ltd. 2018作者: 藥物 時(shí)間: 2025-3-25 04:35 作者: Polydipsia 時(shí)間: 2025-3-25 11:09 作者: 無(wú)辜 時(shí)間: 2025-3-25 15:41 作者: RADE 時(shí)間: 2025-3-25 16:27 作者: initiate 時(shí)間: 2025-3-25 21:17
https://doi.org/10.1057/9780230280762 and host factors can influence the size and characteristics of the HIV reservoir. Constructing effective strategies for HIV eradication and measuring their impact will require a sophisticated knowledge of the HIV reservoir.作者: Blood-Clot 時(shí)間: 2025-3-26 02:28 作者: 拖網(wǎng) 時(shí)間: 2025-3-26 06:33
genomic regions of HIV overestimate the size of the reservoir as they are unable to distinguish between intact and defective virus. As an alternative, sequencing the full-length integrated genome can better distinguish replication-competent provirus, but these methods may be expensive and time-cons作者: Abbreviate 時(shí)間: 2025-3-26 08:48
IV latency in patients on suppressive ART. However, administration of LRAs alone has thus far not demonstrated an effect on the frequency of latently infected cells or the time to virus rebound during analytical interruption of ART. More recently, there has been an enhanced focus on immune-based the作者: Ointment 時(shí)間: 2025-3-26 13:45 作者: 使成核 時(shí)間: 2025-3-26 18:07 作者: 惰性氣體 時(shí)間: 2025-3-27 00:24
In Vitro and In Vivo Models of HIV Latencycal trials. Simian immunodeficiency virus (SIV) infection of Indian origin rhesus macaques has been well established as an informative model of HIV infection. Recent years have seen breakthroughs in ARVs that permit the potent suppression of SIV replication, enabling studies of latency and putative 作者: 致詞 時(shí)間: 2025-3-27 02:21
Measuring HIV Persistence on Antiretroviral Therapy genomic regions of HIV overestimate the size of the reservoir as they are unable to distinguish between intact and defective virus. As an alternative, sequencing the full-length integrated genome can better distinguish replication-competent provirus, but these methods may be expensive and time-cons作者: 相一致 時(shí)間: 2025-3-27 08:22
Clinical Interventions in HIV Cure ResearchIV latency in patients on suppressive ART. However, administration of LRAs alone has thus far not demonstrated an effect on the frequency of latently infected cells or the time to virus rebound during analytical interruption of ART. More recently, there has been an enhanced focus on immune-based the作者: Brain-Waves 時(shí)間: 2025-3-27 09:53
,Correction to: HIV Persistence on Antiretroviral Therapy and Barriers to a?Cure,作者: Pepsin 時(shí)間: 2025-3-27 15:41 作者: 蒼白 時(shí)間: 2025-3-27 18:22
https://doi.org/10.1007/978-3-030-06031-2ed by CD8+ cytotoxic T lymphocytes (CTL). These observations and lessons learned from other viral infections have motivated the development of T-cell vaccine candidates to HIV in the preventive and especially in the therapeutic setting. While none of the T-cell vaccine concepts tested to date have s作者: evaculate 時(shí)間: 2025-3-28 00:29 作者: Traumatic-Grief 時(shí)間: 2025-3-28 03:06
https://doi.org/10.1007/978-981-15-8558-6s that neutralize diverse HIV-1 strains develop in selected HIV-1-infected individuals. The application of single B cell-based approaches has identified many broad and potent human antibodies from infected donors. Structural studies on antibody recognition of HIV Env have revealed that these broadly作者: 蘑菇 時(shí)間: 2025-3-28 07:24 作者: 耐寒 時(shí)間: 2025-3-28 14:19
https://doi.org/10.1007/978-94-6209-725-4rial conducted among serodiscordant couples. Study findings immediately informed global recommendations for the use of treatment as prevention in serodiscordant couples. The extent to which these findings are generalizable to other key populations or to groups exposed to HIV through nonsexual transm作者: 傀儡 時(shí)間: 2025-3-28 15:10 作者: aesthetic 時(shí)間: 2025-3-28 19:21 作者: 調(diào)色板 時(shí)間: 2025-3-29 00:56 作者: Vsd168 時(shí)間: 2025-3-29 03:18
https://doi.org/10.5822/978-1-61091-993-7fected CD4+ T cells in blood. Given the low frequency of infected cells in vivo, multiple in vitro latency models have been developed to facilitate investigations into mechanisms of HIV latency, as well as to enable the evaluation of pharmacological and immunological interventions aimed at depleting作者: 可能性 時(shí)間: 2025-3-29 07:29 作者: 吹牛大王 時(shí)間: 2025-3-29 13:32 作者: 斜 時(shí)間: 2025-3-29 17:15 作者: beta-carotene 時(shí)間: 2025-3-29 20:18
HIV T-Cell Vaccinesed by CD8+ cytotoxic T lymphocytes (CTL). These observations and lessons learned from other viral infections have motivated the development of T-cell vaccine candidates to HIV in the preventive and especially in the therapeutic setting. While none of the T-cell vaccine concepts tested to date have s作者: Endoscope 時(shí)間: 2025-3-30 01:49 作者: minimal 時(shí)間: 2025-3-30 07:16
